Which has higher earnings and valuation, UPB or IMTX?

Upstream Bio has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 110.12 -$143.44M -$2.90 N/A Immatics $54.60M 22.01 -$222.26M -$1.86 N/A

Is UPB or IMTX more profitable?

Immatics has a net margin of -495.71% compared to Upstream Bio's net margin of -4,955.67%. Immatics' return on equity of -47.41% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets Upstream Bio -4,955.67% -48.40% -46.57% Immatics -495.71% -47.41% -39.45%

Which has better earnings and valuation, UPB or MNKD?

MannKind has higher revenue and earnings than Upstream Bio. MannKind is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 110.12 -$143.44M -$2.90 N/A MannKind $393.63M 3.06 $5.86M -$0.13 N/A

Is UPB or MNKD more profitable?

MannKind has a net margin of -11.08% compared to Upstream Bio's net margin of -4,955.67%. MannKind's return on equity of -11.21% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets Upstream Bio -4,955.67% -48.40% -46.57% MannKind -11.08% -11.21% -6.31%

Does the media refer more to UPB or MNKD?

In the previous week, MannKind had 9 more articles in the media than Upstream Bio. MarketBeat recorded 12 mentions for MannKind and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.97 beat MannKind's score of 0.53 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MLTX or UPB?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.97 beat MoonLake Immunotherapeutics' score of 0.32 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to JBIO or UPB?

In the previous week, Jade Biosciences had 3 more articles in the media than Upstream Bio. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Upstream Bio. Jade Biosciences' average media sentiment score of 0.99 beat Upstream Bio's score of 0.97 indicating that Jade Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer JANX or UPB?

In the previous week, Janux Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Janux Therapeutics and 3 mentions for Upstream Bio. Janux Therapeutics' average media sentiment score of 1.36 beat Upstream Bio's score of 0.97 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Upstream Bio (UPB) Competitors

$5.73 -0.02 (-0.35%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$5.72 -0.01 (-0.09%)

As of 09/11/2026 07:30 PM Eastern

Compare

UPB vs. IMTX, MNKD, MLTX, JBIO, and JANX

Should you buy Upstream Bio stock or one of its competitors? Upstream Bio's main competitors and comparable companies include Immatics (IMTX), MannKind (MNKD), MoonLake Immunotherapeutics (MLTX), Jade Biosciences (JBIO), and Janux Therapeutics (JANX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Upstream Bio compare to Immatics?

Upstream Bio (NASDAQ:UPB) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

64.4% of Immatics shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by insiders. Comparatively, 3.3% of Immatics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Upstream Bio had 2 more articles in the media than Immatics. MarketBeat recorded 3 mentions for Upstream Bio and 1 mentions for Immatics. Immatics' average media sentiment score of 1.87 beat Upstream Bio's score of 0.97 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Upstream Bio	Positive
Immatics	Very Positive

Upstream Bio has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A
Immatics	$54.60M	22.01	-$222.26M	-$1.86	N/A

Upstream Bio currently has a consensus price target of $29.67, indicating a potential upside of 417.74%. Immatics has a consensus price target of $20.60, indicating a potential upside of 134.36%. Given Upstream Bio's higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Immatics has a net margin of -495.71% compared to Upstream Bio's net margin of -4,955.67%. Immatics' return on equity of -47.41% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
Immatics	-495.71%	-47.41%	-39.45%

Upstream Bio has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Immatics beats Upstream Bio on 10 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to MannKind?

Upstream Bio (NASDAQ:UPB) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

MannKind has higher revenue and earnings than Upstream Bio. MannKind is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A
MannKind	$393.63M	3.06	$5.86M	-$0.13	N/A

In the previous week, MannKind had 9 more articles in the media than Upstream Bio. MarketBeat recorded 12 mentions for MannKind and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.97 beat MannKind's score of 0.53 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Upstream Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market. Comparatively, MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Upstream Bio currently has a consensus target price of $29.67, suggesting a potential upside of 417.74%. MannKind has a consensus target price of $8.34, suggesting a potential upside of 122.50%. Given Upstream Bio's higher probable upside, equities analysts plainly believe Upstream Bio is more favorable than MannKind.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

49.5% of MannKind shares are held by institutional investors. 16.5% of Upstream Bio shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

MannKind has a net margin of -11.08% compared to Upstream Bio's net margin of -4,955.67%. MannKind's return on equity of -11.21% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,955.67%	-48.40%	-46.57%
MannKind	-11.08%	-11.21%	-6.31%

Summary

MannKind beats Upstream Bio on 10 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.97 beat MoonLake Immunotherapeutics' score of 0.32 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics currently has a consensus price target of $24.57, suggesting a potential upside of 96.41%. Upstream Bio has a consensus price target of $29.67, suggesting a potential upside of 417.74%. Given Upstream Bio's stronger consensus rating and higher probable upside, analysts plainly believe Upstream Bio is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, indicating that its stock price is 28% more volatile than the broader market.

Upstream Bio has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 16.5% of Upstream Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Summary

Upstream Bio beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Jade Biosciences?

Jade Biosciences (NASDAQ:JBIO) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Jade Biosciences has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Jade Biosciences has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Upstream Bio's return on equity of -48.40% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jade Biosciences	N/A	-49.11%	-45.62%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Jade Biosciences has higher earnings, but lower revenue than Upstream Bio. Jade Biosciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A

Jade Biosciences currently has a consensus target price of $51.75, suggesting a potential upside of 189.27%. Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 417.74%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Jade Biosciences had 3 more articles in the media than Upstream Bio. MarketBeat recorded 6 mentions for Jade Biosciences and 3 mentions for Upstream Bio. Jade Biosciences' average media sentiment score of 0.99 beat Upstream Bio's score of 0.97 indicating that Jade Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jade Biosciences beats Upstream Bio on 10 of the 14 factors compared between the two stocks.

How does Upstream Bio compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Upstream Bio (NASDAQ:UPB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Janux Therapeutics had 1 more articles in the media than Upstream Bio. MarketBeat recorded 4 mentions for Janux Therapeutics and 3 mentions for Upstream Bio. Janux Therapeutics' average media sentiment score of 1.36 beat Upstream Bio's score of 0.97 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Upstream Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Janux Therapeutics has a beta of 2.53, meaning that its stock price is 153% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.

Janux Therapeutics has higher revenue and earnings than Upstream Bio. Janux Therapeutics is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	104.55	-$113.62M	-$1.64	N/A
Upstream Bio	$2.85M	110.12	-$143.44M	-$2.90	N/A

75.4% of Janux Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by company insiders. Comparatively, 16.5% of Upstream Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Janux Therapeutics presently has a consensus target price of $36.46, suggesting a potential upside of 113.23%. Upstream Bio has a consensus target price of $29.67, suggesting a potential upside of 417.74%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Janux Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,955.67%. Janux Therapeutics' return on equity of -11.89% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Upstream Bio	-4,955.67%	-48.40%	-46.57%

Summary

Janux Therapeutics beats Upstream Bio on 13 of the 17 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$313.84M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-1.98	14.18	274.94	25.36
Price / Sales	110.12	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	0.91	15.12	10.33	6.20
Net Income	-$143.44M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-4.66%	-4.34%	-3.32%	-2.35%
1 Month Performance	-17.08%	0.54%	-0.53%	-3.23%
1 Year Performance	-67.39%	40.74%	23.51%	8.79%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.6896 of 5 stars	$5.73 -0.3%	$29.67 +417.7%	-67.4%	$313.84M	$2.85M	N/A	38
IMTX Immatics	3.3985 of 5 stars	$9.44 -1.3%	$20.60 +118.2%	+51.0%	$1.31B	$41.70M	N/A	260
MNKD MannKind	2.9276 of 5 stars	$4.16 +2.5%	$8.39 +101.8%	-32.7%	$1.31B	$348.97M	N/A	400	News Coverage Positive News Analyst Forecast
MLTX MoonLake Immunotherapeutics	1.8659 of 5 stars	$14.94 -0.5%	$24.57 +64.5%	-76.2%	$1.28B	N/A	N/A	2
JBIO Jade Biosciences	2.2728 of 5 stars	$19.45 -2.3%	$51.75 +166.1%	+132.3%	$1.27B	N/A	N/A	20	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. IMTX, MNKD, MLTX, JBIO, and JANX

How does Upstream Bio compare to Immatics?

Summary

How does Upstream Bio compare to MannKind?

Summary

How does Upstream Bio compare to MoonLake Immunotherapeutics?

Summary

How does Upstream Bio compare to Jade Biosciences?

Summary

How does Upstream Bio compare to Janux Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. IMTX, MNKD, MLTX, JBIO, and JANX

How does Upstream Bio compare to Immatics?

Do insiders and institutionals believe in UPB or IMTX?

Does the media prefer UPB or IMTX?

Which has higher earnings and valuation, UPB or IMTX?

Do analysts rate UPB or IMTX?

Is UPB or IMTX more profitable?

Which has more volatility and risk, UPB or IMTX?

Summary

How does Upstream Bio compare to MannKind?

Which has better earnings and valuation, UPB or MNKD?

Does the media refer more to UPB or MNKD?

Which has more volatility & risk, UPB or MNKD?

Do analysts rate UPB or MNKD?

Do insiders & institutionals hold more shares of UPB or MNKD?

Is UPB or MNKD more profitable?

Summary

How does Upstream Bio compare to MoonLake Immunotherapeutics?

Does the media favor MLTX or UPB?

Do analysts rate MLTX or UPB?

Which has more volatility and risk, MLTX or UPB?

Which has better valuation and earnings, MLTX or UPB?

Do insiders and institutionals hold more shares of MLTX or UPB?

Is MLTX or UPB more profitable?

Summary

How does Upstream Bio compare to Jade Biosciences?

Which has more volatility and risk, JBIO or UPB?

Is JBIO or UPB more profitable?

Which has preferable valuation & earnings, JBIO or UPB?

Do analysts rate JBIO or UPB?

Does the media refer more to JBIO or UPB?

Summary

How does Upstream Bio compare to Janux Therapeutics?

Does the media prefer JANX or UPB?

Which has more volatility & risk, JANX or UPB?

Which has preferable earnings and valuation, JANX or UPB?

Do institutionals and insiders have more ownership in JANX or UPB?

Do analysts recommend JANX or UPB?

Is JANX or UPB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools